Innovating whole-blood proteomics with VeriPro, our biomarker discovery platform.
The VeriPro platform pairs at-home microsampling with whole-blood proteomics. Biomarkers correlated with gold-standard reference tests become diagnostics conducted on a simple at-home fingerprick blood sample.
A single 30 µL fingerprick whole-blood sample. No clinic visit, no prep, no fasting – mailed back at ambient temperature.
Participants undergo the gold-standard screening disease test – colonoscopy, mammogram or CT – providing the clinical data needed to enable biomarker discovery.
Samples are processed with Sangui Bio's proprietary preparation methods and analysed by mass spectrometry, identifying and quantifying ~4,000 proteins per sample.
Machine learning models are trained on the proteomics data to select a focused biomarker panel that classifies disease status, enabling a blood-based diagnostic from an at-home collected sample.
ColoPro is the lead diagnostic developed on VeriPro: a blood test for colorectal precancerous polyps in high-risk patients in the surveillance cohort. It detects advanced precancerous polyps from a 30 µL fingerprick blood sample collected at home.
The target population is 25 million Americans who have had polyps removed and need ongoing surveillance, a group with no approved blood-based alternative today.
Annual testing, ordered by the gastroenterologist, will return a risk score that enables high-risk patients to be prioritised for follow-up colonoscopy.
Learn more about ColoPro →Sangui Bio operates from the Kolling Institute at Royal North Shore Hospital, a partnership between the Northern Sydney Local Health District and the University of Sydney. The work is grounded in foundational discoveries about blood biochemistry, across a decade of intellectual property development and peer-reviewed research.
Sangui Bio is raising to advance ColoPro through clinical validation. We work with gastroenterology practices, clinical research partners, and strategic investors.